Investors — Clairvoyant Therapeutics

$ 7.00

4.9 (672) In stock

Clairvoyant Therapeutics

2024 Presenting Companies — 2024 OBIO Investment Summit

Psychedelic Portfolio Companies — Iter Investments

Damian Kettlewell, CEO of Clairvoyant Therapeutics, Sits in the

Fluence Raises $3M in Seed Funding

Psychedelics Venture Capital Firm Iter Investments to Exhibit at

Fluence Raises $3 Million to Scale Psychedelic Therapy Training

The Psychedelic News Feed: Dec 11 2023 - Jan 7, 2024 - Psychedelic

Roth Capital Partners Initiates Coverage on Cybin, With Buy Rating

Damian Kettlewell, CEO of Clairvoyant Therapeutics, Sits in the

Portfolio - Origin Therapeutics

clinical trials Archives - Page 7 of 29 - Drug Discovery and

First Alberta Clinical Site for Study of Psychedelic-Assisted

Origin Therapeutics (CSE:ORIG) adds Clairvoyant Therapeutics to

Origin Therapeutics (@OrigTherapeutic) / X